Fulcrum Therapeutics (FULC) Up 65% In A Month, IPO Lockup Expires On Jan.14

Shares of Fulcrum Therapeutics Inc. (FULC) have gained 65 percent over the last one month as the Company progresses with its lead drug candidate Losmapimod in facioscapulohumeral dystrophy.

from RTT - Biotech https://ift.tt/2t2GgnT
via IFTTT